On May 15, 2019 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that data from its isocitrate dehydrogenase (IDH) programs will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held May 31-June 4, 2019 in Chicago (Press release, Agios Pharmaceuticals, MAY 15, 2019, View Source [SID1234536383]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts are listed below and are available online on the ASCO (Free ASCO Whitepaper) conference website: View Source

Oral Presentation:

Title: A phase 1, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1
Date & Time: Monday, June 3, 2019 from 2:15-2:27 p.m. CT
Oral Abstract Session: Central Nervous System Tumors
Abstract: 2003
Location: S102
Presenter: Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center

Poster Presentations:

Title: Ivosidenib (IVO; AG-120) in IDH1-mutant newly diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study
Poster Session Date & Time: Monday, June 3, 2019 from 8:00-11:00 a.m. CT
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7028
Poster Board: 403
Poster Location: Hall A
Author: Gail J. Roboz, M.D., Weill Medical College of Cornell University

Title: Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)
Poster Session Date & Time: Monday, June 3, 2019 from 1:15-4:15 p.m. CT
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7011
Poster Board: 386
Poster Location: Hall A
Author: Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer Center

On May 15, 2019 Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the "Company" or "Ohr") reported financial results for the three and six month periods ended March 31, 2019 (Press release, Ohr Pharmaceutical, MAY 15, 2019, View Source [SID1234536327]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to be excited by the opportunity to merge with NeuBase Therapeutics, a privately-held biotechnology company developing next-generation antisense therapeutics, which we believe offers the best opportunity to generate value for our stockholders. A special meeting for Ohr stockholders to vote on the proposed merger with NeuBase is currently on track to occur in the middle of calendar 2019." said Jason Slakter, M.D., chief executive officer of Ohr Pharmaceutical.

Financial Results for the Second Quarter of FY 2019 ended March 31, 2019:

●For the three months ended March 31, 2019, the Company reported a net loss of approximately $1.1 million, or ($0.40) per share, compared to a net loss of approximately $2.2 million, or ($0.77) per share, in the three months ended March 31, 2018. Loss per share amounts have been retroactively adjusted for the reverse stock split effected on February 4, 2019.
●For the three months ended March 31, 2019, total operating expenses were approximately $1.2 million, consisting of approximately $0.9 million in general and administrative expenses, $0.1 million of research and development expenses, and $0.2 million in depreciation and amortization. This compares to total operating expenses of $2.2 million in the three months ended March 31, 2018, comprised of approximately $0.6 million in general and administrative expenses, $1.8 million in research and development expenses, $0.3 million in depreciation and amortization, $0.7 million in loss on impairment of goodwill, and a $1.2 million gain on settlement of liabilities.
●At March 31, 2019, the Company had cash and cash equivalents of approximately $2.1 million, compared to cash and equivalents of approximately $3.8 million at September 30, 2018.

Financial Results for the Six Months Ended March 31, 2019:

●For the six months ended March 31, 2019, the Company reported a net loss of approximately $2.0 million, or ($0.72) per share, compared to a net loss of approximately $6.3 million, or ($2.25) per share, in the same period of 2018. Loss per share amounts have been retroactively adjusted for the reverse stock split effected on February 4, 2019.
●For the six months ended March 31, 2019, total operating expenses were approximately $2.1 million, consisting of approximately $1.6 million in general and administrative expenses, $0.2 million of research and development expenses, and $0.3 million in depreciation and amortization. This compares to total operating expenses of approximately $6.4 million in the same period of 2018, consisting of approximately $2.1 million in general and administrative expenses, $4.2 million of research and development expenses, $0.6 million in depreciation and amortization, $0.7 million in impairment of goodwill, and $1.2 million in gain on settlement of accounts payable and long term liabilities.

Merger Agreement with NeuBase

On January 3, 2019, Ohr announced entering into a definitive merger agreement with NeuBase under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. The proposed merger has been approved by the board of directors of both companies.

On a pro forma basis and based upon the number of shares of Ohr common stock to be issued in the merger, current Ohr stockholders will own approximately 15% of the combined company and NeuBase stockholders will own approximately 85% of the combined company, after accounting for the additional NeuBase financing transaction. The actual allocation will be subject to adjustment based on Ohr’s and NeuBase’s cash balance at the time of closing and the amount of the additional financing consummated by NeuBase at or before the closing of the proposed merger. Certain members and affiliates of the board of directors and management of Ohr and NeuBase have irrevocably committed to invest in the additional NeuBase financing.

The proposed merger is subject to the approval of Ohr’s stockholders and the satisfaction or waiver of other customary conditions. In connection with the proposed merger, Ohr recently filed with the SEC a pre-effective amendment to its registration statement on Form S-4, which included a joint proxy statement/prospectus.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington’s Disease and Myotonic Dystrophy, as well as other dominant genetic disorders.

Additional Information about the Proposed Merger and Where to Find It

In connection with the proposed merger, Ohr has filed with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that contains a joint proxy statement/prospectus. Investors and security holders of Ohr are urged to read these materials because they contain important information about NeuBase, Ohr and the proposed merger. The joint proxy statement/prospectus, and other relevant materials, and any other documents filed by Ohr with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the registration statement on Form S-4 that contains a joint proxy statement/prospectus by directing a written request to: Ohr Pharmaceutical, Inc., 800 Third Avenue, 11th Floor, New York, NY 10022, Attention: Corporate Secretary. Investors and security holders are urged to read the joint proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed merger.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

The Company and its directors and executive officers and NeuBase and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the proposed merger has been included in the joint proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of the Company is also included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2018 and the proxy statement for the Company’s 2018 Annual Meeting of Stockholders. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Company, Attn: Corporate Secretary, at the address described above.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the structure, timing and completion of the proposed merger; the combined company’s listing on Nasdaq upon the closing of the proposed merger; the financial position and cash balance of the combined company; expectations regarding ownership structure of the combined company; the future operations of the combined company and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company; that the proposed merger will close and will enable the combined company to participate in the possible success of the combined company’s product candidates; that the product candidates have the potential to address critical unmet needs of patients with serious diseases and conditions; and the executive and board structure of the combined company. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those described in the risk factors contained in our filings with the SEC, may cause our actual results to differ from those expressed in forward-looking statements. Ohr and the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Ohr’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Ohr or the combined company could differ materially from those described in or implied by the statements in this press release, including: the risk that the conditions to the closing of the transaction are not satisfied, including the failure to timely or at all obtain stockholder approval for the transaction; uncertainties as to the timing of the consummation of the transaction and the ability of each of Ohr and NeuBase to consummate the transaction; risks related to the combined company’s ability to correctly manage its operating expenses and its expenses; risks related to the market price of Ohr’s common stock relative to the exchange ratio; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger transaction; combined company’s plans to develop and commercialize its product candidates, including NT0100 and NT0200; the timing of initiation of combined company’s planned clinical trials; the timing of the availability of data from combined company’s clinical trials; the timing of any planned investigational new drug application or new drug application; combined company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of combined company’s product candidates; combined company’s commercialization, marketing and manufacturing capabilities and strategy; the combined company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risks discussed under the heading "Risk Factors" in Ohr’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and in any subsequent filings with the SEC. Except as otherwise required by law, Ohr disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

On May 15, 2019 The board of directors of LIDDS AB has reported to carry out a directed issue of 641.200 shares at a subscription price of SEK 13.85 per share (Press release, Lidds, MAY 15, 2019, View Source [SID1234555906]). LIDDS will through the directed share issue receive proceeds amounting to SEK 8.9 million, before transaction costs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The board of directors of LIDDS has, based on the authorization given by the annual general meeting on May 16, 2018, decided to carry out a directed issue of 641.200 shares to Swedish and international investors.

The subscription price in the Directed Share Issue is set to SEK 13.85 and has been determined by closing market price on May 14, 2019. Through the Directed Share Issue, LIDDS will raise SEK 8.9 million before transaction costs. The subscription price in the Directed Share Issue constitutes no discount compared the closing price on 14 May 2019.

The Directed Share Issue entails a dilution of approximately 2.7 percent of the number of shares and the votes in the Company. Through the Directed Share Issue, the number of outstanding shares and votes will increase by 641,200 shares from 23,051,188 shares to 23,692,388 shares. The share capital will increase by SEK 33,983.60 from SEK 1,221,712.96 to SEK 1,255,696.56.

The reason for the deviation from the shareholders’ preferential rights, is to strengthen the shareholder base and to finance LIDDS’ exciting development projects. The Directed Share Issue will primarily be used to finance the NZ-TLR9 project including the Phase I clinical trial of the same proprietary drug candidate.

Subscribers in the Directed Share Issue are Wikow Invest, BWG Invest together with new and existing large shareholders.

Advisers
Advokatfirman Delphi is legal adviser in connection with the Directed Share Issue.

On May 15, 2019 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported an upcoming poster presentation at the 2019 ASCO (Free ASCO Whitepaper) Annual Meeting being held in Chicago, May 31 – June 4, 2019 (Press release, Five Prime Therapeutics, MAY 15, 2019, View Source [SID1234536360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data will be presented from the Phase 1a/1b study of FPA150, which is a first-in-class B7-H4 antibody. The Phase 1a dose escalation portion of the study is being conducted in patients with advanced solid tumors and the Phase 1b expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.

Here are the details of the upcoming poster presentation:

Poster Title: Phase 1a/1b Study of First-in-class B7-H4 Antibody, FPA150 as Monotherapy in Patients with Advanced Solid Tumors
Abstract Number: 2529
Poster Board: 173
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Date & Time: Saturday, June 1, 2019, 8:00 – 11:00am

The poster abstracts will be available on May 15, 2019 at 5:00 PM EST at the ASCO (Free ASCO Whitepaper) Meeting Library and the posters can be found on Five Prime Therapeutics’ Scientific Publications page after presentation at the conference.

About FPA150

FPA150 is a novel, fully human, afucosylated monoclonal antibody targeting B7-H4. B7-H4 expression is observed in multiple solid tumors, including breast and gynecologic cancers. FPA150 is designed with a dual mechanism of action: blocking the T cell checkpoint activity of B7-H4 as well as enhanced ADCC against tumor cells expressing B7-H4.

On May 15, 2019 Eli Lilly and Company (NYSE: LLY) reported that data from a number of studies across the company’s oncology product portfolio will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, May 31-June 4, 2019 (Press release, Eli Lilly, MAY 15, 2019, View Source [SID1234536384]). Data from 23 oral presentations and posters underscore Lilly Oncology’s focus on making a meaningful difference in the lives of people living with cancer, especially those with hard-to-treat tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Lilly data at this year’s ASCO (Free ASCO Whitepaper) demonstrate our commitment to offering treatment solutions for patients with the greatest need. We look forward to sharing these findings, with the hope that they will shed light on our progress and future opportunities in difficult-to-treat cancers," said Maura Dickler, M.D., vice president, late phase development, Lilly Oncology. "We are excited to present the first results from RELAY, a Phase 3 study of ramucirumab in metastatic EGFR-mutated non-small cell lung cancer. Lilly will also share early-phase data from several investigational molecules as well as results from collaborative studies. This includes updated findings from the Phase 3 KEYNOTE-189 study of the pemetrexed-pembrolizumab-platinum chemotherapy combination, which has been established as the standard of care for the treatment of first-line metastatic nonsquamous non-small cell lung cancer."

Lung Cancer Data at ASCO (Free ASCO Whitepaper)

Lilly has a decades-old heritage in developing practice-changing medicines for the treatment of lung cancer. Lilly has developed multiple thoracic oncology treatments and continues to study marketed products and investigational molecules in new combinations and settings where they could help specific patient populations.

RELAY is a global, randomized, double-blind Phase 3 trial evaluating ramucirumab in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have activating EGFR mutations.

The KEYNOTE-189 trial, a randomized, double-blind, placebo-controlled Phase 3 study, evaluated pemetrexed in combination with pembrolizumab and cisplatin or carboplatin compared with pemetrexed in combination with placebo and cisplatin or carboplatin, in untreated patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression. The KEYNOTE-189 study was conducted by Merck (known as MSD outside the U.S. and Canada) in collaboration with Lilly.

Dr. Dickler added, "In addition to our lung cancer data at ASCO (Free ASCO Whitepaper) this year, we will present results of the Phase 3 ANNOUNCE trial, which studied olaratumab in combination with doxorubicin in soft tissue sarcoma. Unfortunately, this study did not confirm a survival benefit seen in a prior Phase 2 trial. We believe it’s important to share these results to inform the scientific community and to apply these learnings to the future investigation of new therapies in this heterogeneous and difficult-to-treat cancer."

Select studies, along with the dates, times and locations of their data sessions, are highlighted below.

Ramucirumab

Abstract #9000: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC) (Kazuhiko Nakagawa)

Oral Abstract Session; Lung Cancer—Non-Small Cell Metastatic
Monday, June 3; 8:00 – 8:12 a.m. CDT; Hall B1
Abstract #2528: Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s) (Yung-Jue Bang)

Poster Session: Poster Board #172; Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #4073: Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2) (Josep M Llovet)

Poster Session: Poster Board #178; Gastrointestinal (Noncolorectal) Cancer
Monday, June 3; 8:00 – 11:00 a.m. CDT; Hall A
Pemetrexed

Abstract #9013: KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC (Shirish M. Gadgeel)

Poster Session, Poster Board #336, Lung Cancer—Non-Small Cell Metastatic
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
Poster Discussion Session on Sunday, June 2; 4:30 – 6:00 p.m. CDT; Hall D1
Olaratumab

Abstract #LBA3: ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS) (William D. Tap)

Plenary Session
Sunday, June 2; 2:45 – 3:00 p.m. CDT; Hall B1
Abemaciclib

Abstract #1017: A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC) (Carey K. Anders)

Poster Session; Poster Board #98; Breast Cancer—Metastatic
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
Poster Discussion Session on Sunday, June 2; 11:15 a.m. – 12:45 p.m. CDT; Hall D2
Abstract #1042: Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data (Erika Paige Hamilton)

Poster Session: Poster Board #123; Breast Cancer—Metastatic
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
LOXO-292

Abstract # TPS10066: A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers (Steven G. DuBois)

Poster Session: Poster Board #447b; Pediatric Oncology
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #10045: First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers (Ulrike Gerdemann)

Poster Session: Poster Board #427; Pediatric Oncology
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
CSF-1R

Abstract #2548: Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC) (Karen A. Autio)

Poster Session: Poster Board #192; Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
ERK Inhibitor

Abstract #3001: A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts) (Shubham Pant)

Oral Abstract Session; Developmental Therapeutics and Tumor Biology (Nonimmuno)
Monday, June 3; 8:12 – 8:24 a.m. CDT; S406
PI3 KINASE/mTOR

Abstract #5009: Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (Christopher Sweeney)

Poster Session: Poster Board #121; Genitourinary (Prostate) Cancer
Saturday, June 1; 1:15 – 4:15 p.m. CDT; Hall A
Poster Discussion Session on Saturday, June 1; 4:30 – 6:00 p.m. CDT; Arie Crown Theater
Prexasertib

Abstract #3091: A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors (David S. Hong)

Poster Session: Poster Board #83; Developmental Therapeutics and Tumor Biology (Nonimmuno)
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
Ralimetinib

Abstract #5537: A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer (Ignace Vergote)

Poster Session: Poster Board #360; Gynecologic Cancer
Saturday, June 1; 1:15 – 4:15 p.m. CDT; Hall A
TIM-3/PD-L1

Abstract #TPS2654: A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors (Matthew David Hellmann)

Poster Session: Poster Board #293a; Developmental Immunotherapy and Tumor Immunobiology
Saturday, June 1; 8:00 – 11:00 a.m. CDT; Hall A
Galunisertib

Abstract #4124: A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer (Davide Melisi)

Poster Session: Poster Board #229; Gastrointestinal (Noncolorectal) Cancer
Monday, June 3; 8:00 – 11:00 a.m. CDT; Hall A
Global Patient Outcomes & Real World Evidence

Abstract #2035: Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM) (Emily Nash Smyth)

Poster Session: Poster Board #224; Central Nervous System Tumors
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #2014: Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC (Melinda D. Willard)

Poster Session: Poster Board #203; Central Nervous System Tumors
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
Poster Discussion Session on Sunday, June 2; 4:30 – 6:00 p.m.; S404
Sintilimab

Abstract #7504: Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4) (Rong Tao)

Oral Abstract Session; Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Tuesday, June 4; 10:57 – 11:09 a.m. CDT; E451
Abstract #4042: Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC) (Nong Xu)

Poster Session: Poster Board #147; Gastrointestinal (Noncolorectal) Cancer
Monday, June 3; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #7533: Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study (Hang Su)

Poster Session: Poster Board #287; Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday, June 3; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #8531: Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (Ning Li)

Poster Session: Poster Board #287; Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 2; 8:00 – 11:00 a.m. CDT; Hall A
Abstract #7534: Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin lymphoma (Hang Su)

Poster Session: Poster Board #288; Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday, June 3; 8:00 – 11:00 a.m. CDT; Hall A
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. P-LLY